Spevigo (spesolimab)
An approved treatment for Generalized Pustular Psoriasis.
Drug facts
The same compound appears under different names depending on the context. Here is how to identify Spesolimab wherever you encounter it, plus the key facts at a glance.
- Generic name
- Spesolimab
- Brand name
- Spevigo
- Development code
- BI 655130
- Drug class
- IL-36 receptor antagonist
- Manufacturer
- LEO Pharma (developed by Boehringer Ingelheim)
- How it's taken
- An infusion into a vein for a flare, and shots under the skin every 4 weeks between flares
An antibody that blocks the IL-36 receptor, approved for generalized pustular psoriasis in adults and children 12 and older who weigh at least 40kg.
- It is given as a 900mg infusion to treat a flare and as a shot under the skin every 4 weeks between flares.
- The FDA first approved it on September 1, 2022 for flares in adults, and LEO Pharma now sells it in the US.
We'll email you when Spevigo's FDA label changes, when the FDA acts on it, and when new trials for Generalized Pustular Psoriasis open. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Where Spesolimab fits
Spevigo was the first IL-36 receptor antibody the FDA approved for generalized pustular psoriasis, according to NORD. Its label covers both an active flare and the time between flares.
- NORD reports that before Spevigo, doctors controlled severe GPP with drugs such as cyclosporine, infliximab, acitretin and antibodies against IL-17 or IL-23.
- Spevigo's 2 main trials compared it only with placebo, which is why its results say nothing about how it stacks up against those older drugs.
- Vanda Pharmaceuticals has a second IL-36 receptor antibody, [imsidolimab](/drugs/imsidolimab), under FDA review with a decision due December 12, 2026.
- ClinicalTrials.gov lists no trial that tests Spevigo against imsidolimab.
- A question to bring to a dermatologist is whether a written flare plan should include the infusion, the monthly shots, or both.
How Spesolimab works
Generalized pustular psoriasis is driven by an inflammation signal in the skin called interleukin-36, or IL-36. A protein called IL-36Ra normally keeps that signal in check, and in some people with GPP a change in the IL36RN gene weakens it[17]. Spesolimab is a humanized antibody that binds the IL-36 receptor. Once it is bound, the IL-36 messengers called alpha, beta and gamma cannot switch the receptor on[1].
The label says the precise link between blocking this receptor and treating GPP flares is unclear[1]. NORD reports that spesolimab has worked even in people with no IL36RN gene change[17].
Side effects and safety
- Severe allergic reactions. Anaphylaxis and DRESS have been reported after the first or later doses; a past severe or life-threatening reaction rules out further use (a contraindication since 2022, updated in October 2025).
- Infections. May raise the risk of infections; not recommended during a clinically important active infection, and stopped if one develops until it is treated; in the first week of the flare trial, 14% on Spevigo had an infection against 6% on placebo.
- Tuberculosis. TB testing before the first dose; not started during active TB; latent TB may be treated first; and watched for signs of TB during and after treatment.
- Infusion reactions. A mild or moderate reaction during the infusion means it is stopped and may be restarted more slowly once the reaction clears. A serious allergic reaction means Spevigo is stopped right away.
- Live vaccines. Avoided during treatment and for at least 16 weeks after; other vaccines are completed before starting.
- Tuberculosis test before the first dose
- Vaccines brought up to date before starting
- Watch for infection and TB symptoms during and after treatment
Spevigo has no boxed warning[1]. Its label has 1 contraindication, present since the 2022 approval and updated in October 2025 to add reported cases of anaphylaxis[7][6]. The label says Spevigo must not be given to anyone who has had a severe or life-threatening allergic reaction to spesolimab or its ingredients. Reported reactions of that kind include anaphylaxis and DRESS, a delayed allergic reaction that can affect the skin and organs[1].
The label's warnings cover infections, tuberculosis, allergic and infusion reactions, and live vaccines. In the first week of the flare trial, the label reports infections in 14% of people on Spevigo against 6% on placebo[1]. The trial paper in the New England Journal of Medicine counts 6 of 35 people, or 17%, with infections in that week[8].
The label does not recommend Spevigo during a clinically important active infection, and it is stopped if one develops until the infection clears or is treated[1]. Doctors test for tuberculosis before the first dose, and the label advises against starting Spevigo during active tuberculosis. Live vaccines are avoided during treatment and for at least 16 weeks after it, and other vaccines are brought up to date before starting[1].
Side effects of the infusion seen in at least 5% of people were weakness or fatigue, headache, nausea and itching. Bruising at the infusion site and urinary tract infection also reached 5%[1]. For the monthly shots, the label counts events per 100 patient-years, meaning per 100 people treated for 1 year. Injection site reactions ran at 31.6 against 12.7 on placebo, and urinary tract infections at 18 against 0.
Joint pain ran at 13.3 against 6, and itching at 8.8 against 0. In the prevention trial, 3 people on the approved dose stopped Spevigo because of psoriasis reported as a side effect, against none on placebo[1].
About 1 in 4 people in each trial, 24%, made high levels of antibodies against the drug that also blocked it. In some of them, blood levels of spesolimab fell significantly[1]. With the monthly shots, the label reports no apparent effect of these antibodies on how well Spevigo worked, though only 11 people with antibodies were studied[1].
Among about 835 people given spesolimab during its development, Guillain-Barre syndrome, a nerve disorder, was reported in 3. All 3 were in studies of conditions other than GPP[1]. The label says pregnancy data are too limited to show a risk, and spesolimab may pass from mother to baby because antibodies of its type cross the placenta[1].
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Spesolimab
Spevigo comes in 2 forms with different jobs. For an active flare, a healthcare professional gives a single 900mg dose as an infusion into a vein over 90 minutes, using 2 vials of 450mg. If flare symptoms persist, a second 900mg infusion may be given 1 week later[1].
Between flares, Spevigo is injected under the skin of the upper thigh or abdomen every 4 weeks. People starting the shots outside a flare get a 600mg loading dose first, then 300mg 4 weeks later and every 4 weeks after that. People starting the shots after an infusion begin with 300mg 4 weeks after it, with no loading dose[1].
The FDA approved a 300mg/2mL prefilled syringe on May 28, 2025[5]. With that syringe, if the healthcare professional decides it is appropriate, a patient 12 or older may self-inject after training, or a caregiver may give the shot[1]. Teenagers aged 12 to 17 inject under adult supervision. With the 150mg/mL syringe, the 600mg loading dose is given by a healthcare professional. The 300mg/2mL syringes can be kept at room temperature, up to 77°F, for up to 14 days in their carton[1].
Availability and cost
Only available as the brand-name product.
A specialty biologic with orphan drug status. LEO Pharma's financial support page describes a copay program, a bridge program and a patient assistance program but gives no list price. Trial Friend did not find a published US list price from LEO Pharma or the FDA.
Help paying for Spevigo
With private insurance, the drugmaker's copay card can lower what you pay for Spevigo. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE. Without insurance, you can apply to the drugmaker's free medicine program, which sets its own eligibility rules. Pick your insurance below to see which offers fit you.
- Copay help
SPEVIGO Copay Program: eligible commercially insured US patients aged 12 and older may pay as little as $0 per treatment. Must be used for an FDA-approved indication; not for Medicare, Medicaid, VA or uninsured patients.
For: private insurance · source - Bridge or quick-start supply
SPEVIGO Bridge Program: people starting the shots under the skin whose coverage is delayed 7 days or more, or denied, may get a limited supply free.
The official page does not say who qualifies. Ask the program. · source - Free medicine program
SPEVIGO Patient Assistance Program: people with financial hardship and limited or no prescription coverage may get Spevigo at no charge. Eligibility looks at household size, income and insurance.
For: no insurance, underinsured · source - Insurance and case manager help
A Clinical Nurse Educator and Navigators help with starting treatment, insurance coverage and out-of-pocket costs. Government-insured and uninsured patients may be able to get information on independent charitable foundations. Call 1-833-SPEVIGO (1-833-773-8446), Monday to Friday, 8am to 8pm Eastern.
For: private insurance, Medicare, Medicaid, no insurance · source
Good to know: LEO Pharma runs the program since taking over Spevigo from Boehringer Ingelheim in 2025. The consent text on LEO's enrollment page prints 1-833-733-8446, while the same page, the financial support page and the letters of 1-833-SPEVIGO give 1-833-773-8446; the record uses 1-833-773-8446.
Clinical trial results
Effisayil-1 (NCT03782792) tested the infusion in 53 adults with a moderate-to-severe flare, 35 on Spevigo and 18 on placebo[10][1]. After 1 week, 19 of 35 people on Spevigo (54%) had no visible pustules, against 1 of 18 on placebo (6%)[1]. The trial paper reports a broader score as well. At week 1, 15 of 35 people on Spevigo (43%) had clear or almost clear skin, against 2 of 18 on placebo (11%)[8].
At week 1, people still in a flare could get an open-label dose, and 34% of the Spevigo group and 83% of the placebo group did[1]. The label calls this first week the trial's placebo-controlled period, so the comparison with placebo covers only that week[1].
Effisayil-2 (NCT04399837) tested the monthly shots in 123 people aged 14 to 75 who had at least 2 earlier moderate-to-severe flares[11][9][1]. Over 48 weeks, 3 of 30 people on the approved dose (10%) had a flare, against 16 of 31 on placebo (52%)[1]. Time to a first flare was also longer on the approved dose, with a hazard ratio of 0.16[9]. The trial included 8 teenagers, 2 in each group, and the 6 who received Spevigo were aged 14 to 17[1].
Effisayil-1 enrolled people who were 55% Asian and 45% White, and Effisayil-2 enrolled people who were 64% Asian and 36% White[1]. Effisayil ON (NCT03886246), a long-term extension now sponsored by LEO Pharma, is active and not recruiting[12].
Development history
Boehringer Ingelheim developed spesolimab under the code BI 655130[3]. The FDA approved Spevigo on September 1, 2022 as an infusion for GPP flares in adults, with orphan drug status[3][2]. On March 18, 2024 the FDA widened the approval to GPP in adults and children 12 and older who weigh at least 40kg[4]. That approval added a prefilled syringe for injection under the skin.
A 300mg/2mL syringe followed on May 28, 2025[5]. On October 21, 2025 the FDA approved label changes on immediate allergic reactions, including anaphylaxis, to the contraindication, warnings and side effect sections[6]. The contraindication itself has been in the label since the 2022 approval[7].
Trial Friend lined up the Drugs@FDA history for the license with the 4 FDA letters on November 18, 2026. The FDA acted on 4 dates in just over 3 years: the first approval, a wider population with the shots, a larger syringe and an update on immediate allergic reactions[2].
LEO Pharma announced on October 1, 2025 that it had closed its deal for Spevigo with Boehringer Ingelheim. The deal itself was first announced on July 14, 2025[13]. LEO's November 6, 2025 results release dates the closing to September 30, 2025[14]. The current US label, revised in March 2026, names LEO Pharma as the distributor[1]. Drugs@FDA still listed Boehringer Ingelheim as the company on the license when Trial Friend checked on November 18, 2026[2].
The 2022 approval letter also required an open-label trial on how antibodies against the drug affect treatment of later flares, with completion scheduled for February 10, 2028[3].
Explore Generalized Pustular Psoriasis trials
Other Generalized Pustular Psoriasis treatments
Common questions about Spesolimab
▸What is Spesolimab (Spevigo)?
An antibody that blocks the IL-36 receptor, approved for generalized pustular psoriasis in adults and children 12 and older who weigh at least 40kg. It is given as a 900mg infusion to treat a flare and as a shot under the skin every 4 weeks between flares. The FDA first approved it on September 1, 2022 for flares in adults, and LEO Pharma now sells it in the US.
▸How does Spesolimab work?
Generalized pustular psoriasis is driven by an inflammation signal in the skin called interleukin-36, or IL-36. A protein called IL-36Ra normally keeps that signal in check, and in some people with GPP a change in the IL36RN gene weakens it[17]. Spesolimab is a humanized antibody that binds the IL-36 receptor. Once it is bound, the IL-36 messengers called alpha, beta and gamma cannot switch the receptor on[1]. The label says the precise link between blocking this receptor and treating GPP flares is unclear[1]. NORD reports that spesolimab has worked even in people with no IL36RN gene change[17].
▸What are the side effects of Spesolimab?
Spevigo has no boxed warning[1]. Its label has 1 contraindication, present since the 2022 approval and updated in October 2025 to add reported cases of anaphylaxis[7][6]. The label says Spevigo must not be given to anyone who has had a severe or life-threatening allergic reaction to spesolimab or its ingredients. Reported reactions of that kind include anaphylaxis and DRESS, a delayed allergic reaction that can affect the skin and organs[1].
The label's warnings cover infections, tuberculosis, allergic and infusion reactions, and live vaccines. In the first week of the flare trial, the label reports infections in 14% of people on Spevigo against 6% on placebo[1]. The trial paper in the New England Journal of Medicine counts 6 of 35 people, or 17%, with infections in that week[8]. The label does not recommend Spevigo during a clinically important active infection, and it is stopped if one develops until the infection clears or is treated[1]. Doctors test for tuberculosis before the first dose, and the label advises against starting Spevigo during active tuberculosis. Live vaccines are avoided during treatment and for at least 16 weeks after it, and other vaccines are brought up to date before starting[1].
Side effects of the infusion seen in at least 5% of people were weakness or fatigue, headache, nausea and itching. Bruising at the infusion site and urinary tract infection also reached 5%[1]. For the monthly shots, the label counts events per 100 patient-years, meaning per 100 people treated for 1 year. Injection site reactions ran at 31.6 against 12.7 on placebo, and urinary tract infections at 18 against 0. Joint pain ran at 13.3 against 6, and itching at 8.8 against 0. In the prevention trial, 3 people on the approved dose stopped Spevigo because of psoriasis reported as a side effect, against none on placebo[1].
About 1 in 4 people in each trial, 24%, made high levels of antibodies against the drug that also blocked it. In some of them, blood levels of spesolimab fell significantly[1]. With the monthly shots, the label reports no apparent effect of these antibodies on how well Spevigo worked, though only 11 people with antibodies were studied[1]. Among about 835 people given spesolimab during its development, Guillain-Barre syndrome, a nerve disorder, was reported in 3. All 3 were in studies of conditions other than GPP[1]. The label says pregnancy data are too limited to show a risk, and spesolimab may pass from mother to baby because antibodies of its type cross the placenta[1].
▸How is Spesolimab taken?
Spevigo comes in 2 forms with different jobs. For an active flare, a healthcare professional gives a single 900mg dose as an infusion into a vein over 90 minutes, using 2 vials of 450mg. If flare symptoms persist, a second 900mg infusion may be given 1 week later[1].
Between flares, Spevigo is injected under the skin of the upper thigh or abdomen every 4 weeks. People starting the shots outside a flare get a 600mg loading dose first, then 300mg 4 weeks later and every 4 weeks after that. People starting the shots after an infusion begin with 300mg 4 weeks after it, with no loading dose[1].
The FDA approved a 300mg/2mL prefilled syringe on May 28, 2025[5]. With that syringe, if the healthcare professional decides it is appropriate, a patient 12 or older may self-inject after training, or a caregiver may give the shot[1]. Teenagers aged 12 to 17 inject under adult supervision. With the 150mg/mL syringe, the 600mg loading dose is given by a healthcare professional. The 300mg/2mL syringes can be kept at room temperature, up to 77°F, for up to 14 days in their carton[1].
▸Is Spesolimab FDA approved?
Yes. The FDA first approved it on September 1, 2022, and the label now covers flares and the time between them.
Who qualifies: adults and children 12 and older with generalized pustular psoriasis who weigh at least 40kg.
Not established: use in children under 12, or in children who weigh under 40kg.
Forms: a 900mg infusion for a flare, and shots under the skin every 4 weeks between flares.
Source: Spevigo prescribing information, March 2026; FDA approval letters, September 1, 2022 and March 18, 2024
▸How is Spevigo given?
As an infusion for a flare and as shots under the skin between flares.
For a flare: a single 900mg infusion into a vein over 90 minutes, given by a healthcare professional, with a second 900mg dose 1 week later if symptoms persist.
Between flares: a 600mg loading dose, then 300mg every 4 weeks. After an infusion, the shots start at 300mg 4 weeks later with no loading dose.
At home: with the 300mg/2mL syringe, if their healthcare professional agrees, patients 12 and older or a caregiver may inject after training, with an adult supervising anyone under 18.
▸What are the side effects of Spevigo?
Infections were the most frequent side effect of the infusion, and Spevigo has no boxed warning.
Infusion: weakness or fatigue, headache, nausea and itching each affected at least 5% of people, as did infusion site bruising and urinary tract infection.
Shots: injection site reactions, urinary tract infection, joint pain and itching were more frequent than on placebo.
Serious: severe allergic reactions, including anaphylaxis and DRESS, can occur with any dose. A past severe reaction rules out further use.
Before starting: a tuberculosis test and up-to-date vaccines, with no live vaccines during treatment and for 16 weeks after.
Source: Spevigo prescribing information, March 2026
▸Who makes Spevigo now?
LEO Pharma sells Spevigo in the US, after taking it over from Boehringer Ingelheim.
The deal: LEO announced on October 1, 2025 that the deal had closed, and its November 6, 2025 results release dates the closing to September 30, 2025.
The label: the March 2026 US label names LEO Pharma Inc. as the distributor and lists LEO's side effect line, 1-877-494-4536.
Support: the SPEVIGO Patient Support Program is at 1-833-773-8446.
Source: LEO Pharma via Business Wire, October 1, 2025; LEO Pharma, November 6, 2025; Spevigo prescribing information, March 2026
▸How much does Spevigo cost, and is there help paying?
LEO Pharma does not give a list price on its Spevigo pages, but it runs several programs that can lower the cost.
Copay: commercially insured US patients aged 12 and older may pay as little as $0 per treatment. Medicare, Medicaid and VA patients are not eligible.
Bridge: people starting the shots whose coverage is delayed 7 days or more, or denied, may get a limited free supply.
No coverage: the SPEVIGO Patient Assistance Program may provide Spevigo at no charge to eligible people with financial hardship.
Call: 1-833-SPEVIGO (1-833-773-8446), Monday to Friday, 8am to 8pm Eastern.
Source: SPEVIGO financial support, LEO Pharma; SPEVIGO Patient Support Program, LEO Pharma
▸Is there a generic or biosimilar of Spevigo?
No. Spevigo is a biologic, so any copy would be a biosimilar, and none is listed.
FDA records: the openFDA Drugs@FDA data list only Spevigo's own license, BLA 761244, for spesolimab.
Source: openFDA Drugs@FDA, checked November 18, 2026
▸Can teenagers use Spevigo?
Yes, from age 12 for those who weigh at least 40kg, for both flares and the time between them.
Evidence: the prevention trial included 6 teenagers aged 14 to 17 who received Spevigo, and drug levels in teenagers were similar to those in adults.
At home: if their healthcare professional agrees, teenagers may inject the 300mg/2mL syringe after training, under adult supervision.
Source: Spevigo prescribing information, March 2026
▸How does Spevigo compare to imsidolimab?
No trial has compared them, so neither can be called better.
Both: antibodies that block the IL-36 receptor in generalized pustular psoriasis.
Status: Spevigo has been approved since 2022. Imsidolimab is under FDA review with a decision due December 12, 2026, and Vanda plans to call it Quimilza.
More: Imsidolimab for GPP
Source: Spevigo prescribing information, March 2026; NORD, July 2024; ClinicalTrials.gov, checked November 18, 2026; Vanda Pharmaceuticals, October 28, 2026
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- U.S. National Library of Medicine, DailyMed · 2026-03-16. DailyMed - SPEVIGO- spesolimab injection. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78a4f7eb-8d34-4467-8d40-74ed24323806
- U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs, Biologic License Application (BLA) 761244. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761244
- U.S. Food and Drug Administration · 2022-09-01. BLA 761244 BLA Approval, Spevigo (spesolimab-sbzo). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/761244Orig1s000ltr.pdf
- U.S. Food and Drug Administration · 2024-03-18. BLA 761244/S-003 Supplement Approval, Spevigo (spesolimab-sbzo). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/761244Orig1s003ltr.pdf
- U.S. Food and Drug Administration · 2025-05-28. BLA 761244/S-004 and S-006 Supplement Approval, Spevigo (spesolimab-sbzo). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/761244Orig1s004,s006ltr.pdf
- U.S. Food and Drug Administration · 2025-10-21. BLA 761244/S-007 Supplement Approval, Spevigo (spesolimab-sbzo). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/761244Orig1s007ltr.pdf
- U.S. Food and Drug Administration · 2022-09-01. SPEVIGO (spesolimab-sbzo) injection, for intravenous use, Prescribing Information (Revised 09/2022). https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761244s000lbl.pdf
- New England Journal of Medicine · 2021-12-23. Trial of Spesolimab for Generalized Pustular Psoriasis. https://pubmed.ncbi.nlm.nih.gov/34936739/
- The Lancet · 2023-10-28. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. https://pubmed.ncbi.nlm.nih.gov/37738999/
- ClinicalTrials.gov. Effisayil 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis. https://clinicaltrials.gov/study/NCT03782792
- ClinicalTrials.gov. A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis. https://clinicaltrials.gov/study/NCT04399837
- ClinicalTrials.gov. Effisayil ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study. https://clinicaltrials.gov/study/NCT03886246
- LEO Pharma via Business Wire · 2025-10-01. LEO Pharma Closes Deal for Spevigo®. https://www.businesswire.com/news/home/20251001965112/en/LEO-Pharma-Closes-Deal-for-Spevigo
- LEO Pharma · 2025-11-06. LEO Pharma delivers 8% revenue growth at CER in 9M 2025 and updates full-year outlook. https://leo-pharma.com/media-center/news/2025-q3-results/
- LEO Pharma · 2026-10. Financial Support | SPEVIGO® (spesolimab-sbzo). https://www.spevigo.com/savings-and-support/financial-support
- LEO Pharma · 2026-04. Patient Support Program | SPEVIGO® (spesolimab-sbzo). https://www.spevigo.com/savings-and-support/spevigo-patient-support-program
- National Organization for Rare Disorders · 2024-07-11. Generalized Pustular Psoriasis - Symptoms, Causes, Treatment | NORD. https://rarediseases.org/rare-diseases/generalized-pustular-psoriasis/
- Vanda Pharmaceuticals via PR Newswire · 2026-10-28. Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results. https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-reports-third-quarter-2026-financial-results-302922677.html